隶属于 jiangsu hengrui pharmaceutical group co. ltd.
相关临床试验
5
5 进行中
药物批准
3
批准总数
监管机构
2
监管机构数
成立时间
1997
进行中（未招募）
5
100.0%
- Hengrui Pharma and Novaliq announced NMPA approval of Heng Yi (0.1% cyclosporine ophthalmic solution) on June 23, 2026, for the treatment of dry eye disease. - Heng Yi is the first and only water-free cyclosporine ophthalmic solution in China, based on Novaliq's EyeSol platform, and the second EyeSol-based product approved in the country. - The Phase III SHR8028-301 bridging trial met its primary endpoint, demonstrating a statistically significant reduction in total corneal fluorescein staining score at Day 29 (treatment: −4.8 vs control: −3.0; P<0.0001). - The approval positions Hengrui to address both aqueous-deficient and evaporative dry eye subtypes through a combined portfolio with previously approved Heng Qin.
- Hengrui's Phase 2 trial of oral ribupatide showed participants achieved mean weight loss up to 12.1% with no plateau at Week 26, with 38.6% achieving at least 15% weight loss. - Kailera presented Phase 1 bridging study data for ribupatide injection at ADA 2026, supporting their ongoing global Phase 3 KaiNETIC clinical program. - The companies are advancing multiple formulations of ribupatide, a GLP-1/GIP receptor dual agonist, including oral and injectable versions for obesity treatment. - Kailera initiated a U.S. Phase 2b high-dose obesity trial evaluating up to 20 mg ribupatide injection doses in 250 participants over 48 weeks.
- HRS-1893, a next-generation cardiac myosin inhibitor, demonstrated rapid and substantial reductions in left ventricular outflow tract gradient with up to 86% complete response rates in a 42-patient Phase 2 study. - The investigational therapy showed minimal impact on left ventricular ejection fraction (1.8-2.7% decrease) while achieving target gradient reduction below 30 mmHg as early as day 5. - Results suggest potential for simplified dosing with minimal titration requirements, addressing key limitations of current therapies for obstructive hypertrophic cardiomyopathy. - The positive data support initiation of a global pivotal clinical study planned for 2026, marking a significant advancement in treatment options for this cardiac condition.
- Kailera Therapeutics has begun randomizing participants in its KaiNETIC global Phase 3 program for ribupatide, a dual GLP-1/GIP receptor agonist targeting obesity treatment. - Previous Chinese trials demonstrated impressive weight loss results, with ribupatide achieving 23.6% weight reduction after 36 weeks compared to 1.8% with placebo. - The comprehensive Phase 3 program includes three trials enrolling over 4,700 participants across multiple regions, with doses up to 10 mg evaluated over 76 weeks. - The program specifically targets patients with severe obesity (BMI ≥35 kg/m²), addressing a critical unmet need as this population is projected to represent half of U.S. adults with obesity by 2030.
- AbbVie has signed a $1.1 billion licensing deal with China's Zelgen Biopharmaceuticals for global rights to alveltamig (ZG-006), a trispecific T-cell engager targeting DLL3-expressing tumors. - The agreement includes a $100 million upfront payment and up to $1.075 billion in potential milestone payments, with Zelgen retaining commercialization rights in Greater China. - Alveltamig is currently in Phase I/II trials for small cell lung cancer and neuroendocrine carcinoma, targeting DLL3 which is expressed in over 70% of small cell lung cancers. - This deal represents the latest in a series of major DLL3-focused partnerships, following similar billion-dollar agreements by Hengrui Pharma and Innovent Bio in recent years.
- China's 2025 National Reimbursement Drug List successfully added 114 drugs with an 88% success rate, including 50 Class I innovative drugs, marking significant support for genuine pharmaceutical innovation. - All five CAR-T cell therapies achieved breakthrough inclusion in the inaugural commercial insurance innovative drug directory, alongside 19 total innovative drugs, creating new payment pathways for high-value treatments. - The dual-track "basic medical insurance + commercial health insurance" model addresses previous cost-effectiveness barriers for expensive therapies while maintaining focus on clinical value and unmet medical needs. - Major pharmaceutical companies including Hengrui Pharma, Innovent Bio, Pfizer, and Johnson & Johnson secured multiple product inclusions, with Alzheimer's treatments and rare disease therapies gaining commercial insurance coverage.
- Elevar Therapeutics' Phase 3 CARES-310 study published in The Lancet Oncology demonstrates that rivoceranib plus camrelizumab significantly improved overall survival compared to sorafenib in unresectable hepatocellular carcinoma patients. - The combination therapy achieved a median overall survival of 23.8 months versus 15.2 months with sorafenib, representing a 36% reduction in death risk with manageable safety profile. - The company plans to resubmit its New Drug Application to the FDA for the combination therapy in January 2026, potentially offering a new first-line treatment option for liver cancer patients.
- Braveheart Bio secured $185 million in Series A funding to develop BHB-1893, a cardiac myosin inhibitor licensed from China's Hengrui Pharma for treating hypertrophic cardiomyopathy. - The drug aims to challenge Bristol Myers Squibb's Camzyos, currently the only approved treatment for the condition, which generated $843 million in sales over nine months. - BHB-1893 is already in Phase 3 testing in China for obstructive hypertrophic cardiomyopathy, with global late-stage trials planned to begin in 2026. - Phase 1 data presented in August demonstrated rapid and clinically meaningful impact on blood flow with a safety profile supporting simple dosing regimens.
- Merck plans to slash $3 billion in costs by the end of 2027 to reinvest in new product launches and drug pipeline development ahead of Keytruda's patent expiration in 2028. - The company reported second-quarter revenue of $15.81 billion, missing Wall Street estimates for the first time since April 2021, driven by a 55% decline in Gardasil sales due to weak demand in China. - Keytruda sales grew 9% to $7.96 billion during the quarter, driven by higher uptake for earlier-stage cancers and strong demand for metastatic cancer treatment. - The restructuring program will eliminate certain administrative, sales, and R&D positions while reducing global real estate footprint and manufacturing network optimization.
- GSK announced a strategic partnership with Chinese pharmaceutical firm Hengrui Pharma worth up to $12 billion to develop 12 medicines across respiratory, immunology, inflammation, and oncology therapeutic areas. - The deal includes an exclusive worldwide license for HRS-9821, a potential best-in-class PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease treatment. - GSK will pay $500 million in upfront fees and up to $12 billion in success-based milestone payments, with Hengrui eligible for tiered royalties on global sales outside Greater China. - The partnership aims to add significant growth opportunities beyond 2031 and expand COPD treatment options for patients with continued dyspnea or those unsuitable for inhaled corticosteroids or biologics.
